Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Great news for CYCC on Thursday and it will be curious to see what happens to the stock on Friday. Some people on message boards are saying it will reach $5 or more. We'll see. There certainly will be profit-taking on Friday. I want to share the following from Bio Health Investor with you to keep things in perspective:

10-Bagger Watch: Cyclacel Meets Biotech Trophy Hunters (CYCC)

Cyclacel has three orally available Cyclacel drugs in clinical development:

• 1. Sapacitabine is a cell cycle modulating nucleoside analog in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010.
• 2. Seliciclib (the big news winner Thursday) is a cyclin dependent kinase inhibitor in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.
• 3. CYC116 is a Aurora kinase and VEGFR2 inhibitor in a Phase 1 trial in patients with solid tumors.

I painfully wish I had more than just 300 shares of this.